Pipeline
TO RE-ARM the immune system at speed
Our unique ProTcell platform has broad application potential, including hematology post-transplant and in combination with immuno-oncology therapies. We are also developing CAR ProTcell, towards well-tolerated and persistent off-the-shelf allogeneic CAR-T cells.
ProTcell is a T-cell progenitor-based allogeneic cell therapy designed to rapidly rebuild a fully polyclonal T-cell compartment in 100 days after an allogenic hematopoietic stem cell transplantation (allo-HSCT), versus the 18 months needed in the current medical practice.
Once infused into the patients, the ProTcells migrate into the patient’s thymus to be differentiated and give rise to a large pool of polyclonal, long-lasting T-cell population able to fight cancers and infections in the long run.
SMART101 is manufactured from peripheral mobilized blood stem cells. It is currently studied in 3 phase I/II clinical trials:
- in Europe in patients with severe combined immunodeficiency (SCID) (NCT03879876)
- the ReSET-01 trial in the United States in adult and pediatric patients with high-risk acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL) (NCT04959903).
- the ReSET-02 trial in Europe in adult patients with high-risk AML, ALL or myelodysplastic syndrome (MDS) (NCT05768035)
It will also be studied in additional trials, ReSET-03, in primary immune deficiencies (PIDs), and ReBOOST-01 in immuno-oncology, in association with bi-specific T cell engagers and immune checkpoints inhibitors.
SMART201 is the allogeneic off-the-shelf CAR ProTcell to be produced from mobilized peripheral blood.